Colorectal cancer (CRC) is a preventable disease, but still claims many lives because we have yet to optimally implement preventive therapies. One of the biggest challenges is the fact that CRC is not a single uniform disease, but rather a complex multifactoral process with variable expression in susceptible individuals. Developing safe and effective chemoprevention for CRC requires understanding the nature of early colorectal tumorigenesis in actual patients at risk for this disease and following through to test new mechanistically valid chemopreventive agents in human clinical trials. Few research centers have the experienced investigators, resources, and supportive infrastructure required for successful completion of cancer chemoprevention trials. As a result, there is a great need to train new investigators to conduct this important research. Dr. Monica Bertagnolli is an experienced translational researcher in colorectal cancer (CRC) prevention. She is the Lead Principal Investigator of the recently completed Adenoma Prevention with Celecoxib (APC) Trial, a randomized placebo-controlled study of more than 2000 patients at high risk for CRC. She also directs a laboratory studying the biology of pre-malignant adenomas and the tissue-specific effects of chemopreventive compounds. This proposal for an established investigator career development award outlines a plan for Dr. Bertagnolli to spend a significant amount of time over the next 5 years mentoring junior faculty members in cancer prevention research. She will use the considerable clinical data and tissue resources of the APC Trial to provide advisees with the raw materials necessary to conduct studies of modifiable factors in CRC development and chemopreventive drug response. She also establish a multidisciplinary forum for presentation, discussion, and critique of ongoing work in Gl cancer prevention, aided by senior Dana Farber-Harvard Cancer Center investigators and outside consultants. Conducting high quality translational research in a manner that optimizes educational potential is extremely time consuming, and Dr. Bertagnolli is one of the few individuals who can succeed in this task. The support provided by this award will allow Dr. Bertagnolli to complete key research projects using APC Trial resources in a manner that facilitates maturation of junior faculty into independent researchers in cancer prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Scientist Award (K05)
Project #
5K05CA131504-05
Application #
8210886
Study Section
Subcommittee G - Education (NCI)
Program Officer
Perkins, Susan N
Project Start
2008-01-01
Project End
2013-02-01
Budget Start
2012-01-01
Budget End
2013-02-01
Support Year
5
Fiscal Year
2012
Total Cost
$163,042
Indirect Cost
$12,077
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Hasson, Rian M; Briggs, Alexandra; Carothers, Adelaide M et al. (2014) Estrogen receptor * or * loss in the colon of Min/+ mice promotes crypt expansion and impairs TGF* and HNF3* signaling. Carcinogenesis 35:96-102
Cho, Nancy L; Carothers, Adelaide M; Rizvi, Hira et al. (2012) Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors. J Surg Res 173:320-6
Carothers, Adelaide M; Rizvi, Hira; Hasson, Rian M et al. (2012) Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. Cancer Res 72:346-55
Davids, Jennifer S; Carothers, Adelaide M; Damas, Beatrice C et al. (2010) Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis. Cancer Prev Res (Phila) 3:348-58
Chan, Andrew T; Zauber, Ann G; Hsu, Meier et al. (2009) Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 136:2127-2136.e1
Bertagnolli, Monica M; Eagle, Craig J; Zauber, Ann G et al. (2009) Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2:310-21